Zealand Pharma slides after obesity drug data

Zealand Pharma A/S

08/10/2026 12:08

       ** Shares in Zealand Pharma ZELA.CO fall around 4%, analysts say experimental obesity drug petrilintide developed with Roche ROPC.S underwhelmed on blood sugar control data
** Wider healthcare sector also down, STOXX healthcare index .SXDP -1.8% at 1107 GMT
** Brokerage William Blair says that while tolerability of the drug was encouraging, the weight loss and reduction in average blood sugar levels "disappointed"
** KBC Securities says the drug will unlikely emerge as "the best-in-class amylin"
** It cuts its peak-sales estimates for petrelintide to $3 billion from $7 billion, citing also heating up pricing pressure in obesity drugs
** It also cuts its rating on the stock to "hold", lowering PT by 42% to 290 Danish crowns
     
     
     

(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))